Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Read More 6 minute read Pharma Industry News Lupin launches authorized generic of PENNSAID in US to tap $509m osteoarthritis knee pain market Lupin launches the authorized generic of PENNSAID in the U.S., targeting the $509M osteoarthritis knee pain market with a proven, cost-effective NSAID solution. byPallavi MadhirajuDecember 11, 2022